PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
PostNews: Press Release
PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history
PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.
PostNews: Interim Report
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
PostNews: Press Release
PHI appoints Pareto Securities AB to act as a liquidity provider for the Company’s share
PHI has appointed Pareto Securities as the Company’s liquidity provider.
PostNews: Press Release
PHI granted patent on synthetic antibodies in the EU
PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.
PostNews: Press Release
Directed issue registered at the Companies Registration Office
PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
Label-free High Content Screening
The current form of high-content screening is based on conventional microscopy. The core technology of HoloMonitor, holographic time-lapse microscopy, creates 3D-movies of unstained living cells that can be computer-processed without requiring the use of toxic labels. This new ability opens the door to more realistic high-content screening of living cells and their behavior over time.
Immunothearpy
The progress by Northeastern University and other customers have shown that HoloMonitor technology has the potential to be the non-destructive tool that makes large scale immunotherapies successful and affordable to all patients.
AACR 2015
Our participation at the AACR 2015 was further strengthened by three presentations by scientists associated with the Center of Excellence for holographic imaging at Northeastern University in Boston, USA.
Interim Report
When traveling I have the habit of picking up Scientific American, a popular science magazine published by Nature Publishing Group. While casually browsing the first few pages of the February issue, I suddenly froze on page 5. On this page, Hamamatsu Photonics has a full page ad presenting their holographic phase imaging research.
